#AS­CO19: MET in­hibitors from In­cyte/No­var­tis and Ger­many's Mer­ck face off for rare sub­set of NSCLC pa­tients

CHICA­GO — Tout­ed as one of No­var­tis’ block­busters-to-be in 2020, the In­cyte-dis­cov­ered MET in­hibitor cap­ma­tinib is be­ing primed for a mar­ket­ing ap­pli­ca­tion af­ter fi­nal da­ta from a mid-stage study sug­gest­ed the drug has the abil­i­ty to im­prove out­comes in pa­tients with non small cell lung can­cer (NSCLC) har­bor­ing a MET ex­on-14 skip­ping mu­ta­tion — a sub­set that has no ap­proved tar­get­ed ther­a­py.

Ac­cord­ing to the NIH, MET ex­on 14 skip­ping oc­curs in rough­ly 5% of pa­tients with NSCLC, which rep­re­sents the most com­mon form of lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER